ImmuPharma PLC (LSE:IMM) has unveiled a newly redesigned corporate website : https://www.immupharma.co.uk/, spotlighting its innovative P140 autoimmune platform. This platform offers a novel therapeutic approach aimed at restoring immune system balance to treat autoimmune diseases more effectively.
Alongside this, the company is developing a companion diagnostic tool to enable more precise patient monitoring. ImmuPharma is actively exploring strategic partnerships to commercialize the P140 platform and aims to secure a deal by the end of 2025.
On the financial front, the company has extended its cash runway into the second half of 2026 and is looking to further strengthen its financial position through potential collaborations and licensing opportunities.
About ImmuPharma PLC
ImmuPharma is a biopharmaceutical company specializing in the development of peptide-based therapies. Its portfolio focuses on innovative treatments for autoimmune disorders and infectious diseases, leveraging novel peptide science to address high unmet medical needs.
Leave a Reply